The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
 
Karim Chamie
Honoraria - Urogen pharma
Consulting or Advisory Role - ImmunityBio; Urogen pharma
Speakers' Bureau - Urogen pharma
Research Funding - Salix; Urogen pharma
 
Sam S. Chang
Honoraria - CG Oncology; FerGene; Janssen Oncology; Merck; miR Diagnostics LLC; Urogen pharma
Consulting or Advisory Role - CG Oncology; Janssen Oncology; Merck; NantBioScience; Pfizer; Photocure; Urogen pharma; UroToday; virtuoso Surgical
Research Funding - NantCell (Inst)
 
Mark Gonzalgo
No Relationships to Disclose
 
Eugene V. Kramolowsky
No Relationships to Disclose
 
Wade J. Sexton
No Relationships to Disclose
 
Paul Bhar
Employment - ImmunityBio
Stock and Other Ownership Interests - ImmunityBio
 
Sandeep K. Reddy
Employment - ImmunityBio
Leadership - ImmunityBio
Stock and Other Ownership Interests - NantHealth
 
Patrick Soon-Shiong
Employment - ImmunityBio; NantHealth; NantWorks
Leadership - ImmunityBio; NantHealth; NantWorks
Stock and Other Ownership Interests - ImmunityBio; NantHealth; NantWorks
Patents, Royalties, Other Intellectual Property - NantWorks & Affiliates, NantKwest, ImmunityBio